Abstract
Background: Copanlisib, a pan-PI3K inhibitor with stronger activity against the alpha and delta isoforms, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is has shown clinical activity in other indolent lymphomas including marginal zone lymphoma (MZL). Preclinical studies have demonstrated strong synergism of copanlisib and BCL2 inhibitor venetoclax in different lymphomas (Tarantelli Blood Adv 2020). A phase 1 study has explored this specific combination (NCT03886649), while others have explored similar schemes based on dual PI3K and BCL2 targeting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
